LSZ: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
[[File: | [[File:Lsz_blotter.jpg|250px|right]] | ||
LSZ, also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent. | '''LSZ''', also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent. | ||
= Dosage = | == Dosage == | ||
Light | {| class="wikitable" | ||
|+ Oral | |||
| Threshold || 80ug | |||
|- | |||
| Light || 100-150μg | |||
|- | |||
| Common || 150-300μg | |||
|- | |||
| Strong || 300μg+ | |||
|} | |||
== Duration == | |||
{| class="wikitable" | |||
|+ Oral | |||
|- | |||
| Onset || 90-120 minutes | |||
|- | |||
| Duration || 7-10 hours | |||
|- | |||
| After-effects || 1-24 hours. | |||
|} | |||
= | == Effects == | ||
While LSZ has subtly different effects than LSD, with a slightly shorter duration while also having a longer comeup. | |||
== Harm Reduction == | |||
While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to [[LSD]]. Refer to [[LSD]] and [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for more information. | |||
== Images == | |||
<gallery mode="packed-hover"> | |||
Image:LSZ.jpg|''LSZ'' | |||
</gallery> | |||
= | == Legal status == | ||
* | *USA: Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption. | ||
Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption. | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Psychedelic]] | [[Category:Psychedelic]] | ||
[[Category:Research Chemical]] | |||
Latest revision as of 19:36, 16 October 2016
LSZ, also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent.
Dosage
| Threshold | 80ug |
| Light | 100-150μg |
| Common | 150-300μg |
| Strong | 300μg+ |
Duration
| Onset | 90-120 minutes |
| Duration | 7-10 hours |
| After-effects | 1-24 hours. |
Effects
While LSZ has subtly different effects than LSD, with a slightly shorter duration while also having a longer comeup.
Harm Reduction
While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to LSD. Refer to LSD and Psychedelic Harm Reduction for more information.
Images
-
LSZ
Legal status
- USA: Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.